Oral liquids · Contract manufacturing in India

Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg · Oral drops

Discuss third-party manufacturing of Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg Oral drops with Walter Healthcare, India. Share your target market, required bottle count and fill volume, packaging and launch timeline for a product-specific quotation.

Catalogue reference: WH-5575
Composition and strength: Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg
Dosage form: Oral drops
Indicative administration route: Oral
Therapeutic navigation area: Haematology & thrombosis
Pharmacological class: Iron replacement / haematinic
Manufacturing stream: Non-beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Editorial development perspective

What deserves attention in this formulation.

These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.

A matching clinical reference has not yet been verified for this page. Drug-specific mechanisms and human pharmacokinetic values remain open for review.

About these development notes and source limitations ↗

Treat the dropper as part of the presentation

Listed presentation: Oral drops.

Define the concentration and the proposed measuring convention before selecting a dropper. Check delivery consistency with the actual formulation and container. A bottle-volume specification alone does not describe the quantity delivered by the accessory; the development brief should connect the concentration, device and intended label wording.

Carry the exact ingredient form into development

Catalogue wording: “Trihydrate”.

Use the named ingredient form when requesting material specifications and comparing possible suppliers. Resolve assay, water-content and strength-equivalence conventions before converting a formula into batch quantities. A similarly named salt or hydrate should be assessed as a distinct material choice rather than introduced through a naming shortcut.

Resolve the amount-per-container or concentration basis

Strength expressions in this entry include “25 mg”.

Clarify whether each stated amount applies to a complete container, a defined volume or a defined weight. Put the agreed denominator beside the ingredient quantity before comparing formula costs or designing a label. Keep the finished fill size as a separate field so that changing the pack does not silently change the intended specification.

Suggested starting point

A practical starting point is to carry the exact ingredient form into development. For this oral drops brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.

Discuss this product brief

Manufacturing & packaging brief

Plan the oral-drop presentation.

Use this preparation guide for Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg Oral drops. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

State the concentration per defined volume and identify the oral route. Include the proposed fill volume and any established formula requirements.

Quality & technical transfer

Request review of the product specification, analytical methods and delivery accuracy of the proposed dropper or dosing accessory.

Review the technical documents

Packaging configuration

Specify the bottle material, dropper or oral dosing device, closure and carton. Confirm compatibility and supported in-use statements for that pack.

Explore packaging options

Details to confirm for this record

Concentration and pack size: The record does not state a complete concentration basis. Confirm the amount per volume or weight before a specification, label or quotation is finalised; no denominator has been assumed here.

Quantities, MOQ & lead time

For Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg Oral drops, state the bottle count and fill volume, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Dosage-form capabilitiesOral liquids Therapeutic navigationHaematology & thrombosis Full catalogueSearch other compositions

Common questions

Before you request a quotation.

Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg Oral drops

What is listed in the catalogue?

The catalogue lists Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg as oral drops in its haematology & thrombosis navigation area and non-beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg Oral drops. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, oral drops presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg Oral drops. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas

Site, licence and audit scope: Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release: Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification: Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities: Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times: Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence: Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport: Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer: Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes: Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks: API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable: Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity: Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support: Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements: Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that Ferrous Ethylene Diamine Tetra Acetate Trihydrate 25 mg Oral drops is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated 8 October 2026.